IDEAYA Biosciences, Inc. (IDYA) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
IDYA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
IDYA Revenue Analysis (2017–2025)
As of March 1, 2026, IDEAYA Biosciences, Inc. (IDYA) generated trailing twelve-month (TTM) revenue of $218.7 million, reflecting explosive growth of +55.4% year-over-year. The most recent quarter (Q4 2025) recorded $10.9 million in revenue, down 94.8% sequentially.
Looking at the longer-term picture, IDYA's 5-year compound annual growth rate (CAGR) stands at +62.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $218.7 million in 2025, representing a new all-time high.
Revenue diversification analysis shows IDYA's business is primarily driven by Research and Development Services (100%). With over half of revenue concentrated in Research and Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY), IDYA has underperformed the peer group in terms of revenue growth. Compare IDYA vs INCY →
Peer Comparison
Compare IDYA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IDYACurrent | $219M | +55.4% | +62.1% | -72.8% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $218.7M | +3024.4% | $214.1M | 97.9% | $-159,313,000 | -72.8% |
| 2024 | $7.0M | -70.1% | $3.2M | 45.2% | $-326,975,000 | -4671.1% |
| 2023 | $23.4M | -54.1% | $19.4M | 82.9% | $-134,429,000 | -574.9% |
| 2022 | $50.9M | +82.3% | $48.8M | 95.9% | $-62,502,000 | -122.7% |
| 2021 | $27.9M | +43.0% | $26.2M | 93.8% | $-50,268,000 | -179.9% |
| 2020 | $19.5M | - | $18.2M | 92.9% | $-35,344,000 | -180.9% |
| 2019 | $0 | - | $-1,245,000 | - | $-44,271,000 | - |
| 2018 | $0 | - | $-886,000 | - | $-36,417,000 | - |
| 2017 | $0 | - | $-391,000 | - | $-14,438,000 | - |
See IDYA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IDYA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IDYA vs AGIO
See how IDYA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is IDYA's revenue growth accelerating or slowing?
IDYA revenue is accelerating at +55.4% year-over-year, exceeding the 5-year CAGR of +62.1%. TTM revenue reached $219M. Growth momentum has increased versus prior periods.
What is IDYA's long-term revenue growth rate?
IDEAYA Biosciences, Inc.'s 5-year revenue CAGR of +62.1% reflects the sustained expansion pattern. Current YoY growth of +55.4% is above this long-term average.
How is IDYA's revenue distributed by segment?
IDYA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.